BR112018075363A2 - neurotoxinas botulínicas manipuladas - Google Patents

neurotoxinas botulínicas manipuladas

Info

Publication number
BR112018075363A2
BR112018075363A2 BR112018075363-7A BR112018075363A BR112018075363A2 BR 112018075363 A2 BR112018075363 A2 BR 112018075363A2 BR 112018075363 A BR112018075363 A BR 112018075363A BR 112018075363 A2 BR112018075363 A2 BR 112018075363A2
Authority
BR
Brazil
Prior art keywords
manipulated
modified
serotype
botulinum neurotoxins
receptor binding
Prior art date
Application number
BR112018075363-7A
Other languages
English (en)
Inventor
Stenmark Paul
Zhang Sicai
Dong Min
Original Assignee
Children's Medical Center Corporation
Stenmark Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation, Stenmark Paul filed Critical Children's Medical Center Corporation
Publication of BR112018075363A2 publication Critical patent/BR112018075363A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)

Abstract

são descritos aqui polipeptídeos modificados de neurotoxina de clostridium botulinum (bont) com um domínio de ligação a receptor modificado de clostridium botulinum de serotipo b que compreendem uma ou mais mutações de substituição em posições que correspondem a 1248 ou 1249 no serotipo b, cepa 1. mutações de substituição específicas incluem i1248f, i1248y, i1248h, i1248w, v1249w, v1249f, v1249y, v1249h, i1248w/v1249f, i1248w/v1249y, i1248w/v1249h, i1248f/v1249y, i1248f/v1249h, i1248y/v1249h, i1248f/v1249w, i1248y/v1249w, i1248h/v1249w, i1248y/v1249f, i1248h/v1249f ou i1248h/v1249y. outras mutações de substituição também são descritas. domínios de ligação a receptor modificados isolados, moléculas quiméricas, composições farmacêuticas e métodos de uso das mesmas também são descritos.
BR112018075363-7A 2016-06-08 2017-06-08 neurotoxinas botulínicas manipuladas BR112018075363A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347579P 2016-06-08 2016-06-08
US62/347,579 2016-06-08
PCT/US2017/036628 WO2017214447A1 (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Publications (1)

Publication Number Publication Date
BR112018075363A2 true BR112018075363A2 (pt) 2019-03-19

Family

ID=59227906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075363-7A BR112018075363A2 (pt) 2016-06-08 2017-06-08 neurotoxinas botulínicas manipuladas

Country Status (13)

Country Link
US (1) US11104891B2 (pt)
EP (1) EP3468985A1 (pt)
JP (2) JP7152392B2 (pt)
KR (1) KR20190025906A (pt)
CN (1) CN109476713A (pt)
AU (1) AU2017277905B2 (pt)
BR (1) BR112018075363A2 (pt)
CA (1) CA3026492A1 (pt)
EA (1) EA201892784A1 (pt)
IL (1) IL263058B2 (pt)
MX (1) MX2018015254A (pt)
SG (2) SG11201810210UA (pt)
WO (1) WO2017214447A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2854840T (pt) 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
HUE057258T2 (hu) * 2015-03-26 2022-05-28 Harvard College Szerkesztett Botulinum neurotoxin
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
MX2018014066A (es) * 2016-05-16 2019-04-04 Harvard College Metodo para purificacion y activacion de la neurotoxina botulinica.
MX2019000151A (es) * 2016-07-08 2019-08-29 Childrens Medical Center Una neurotoxina botulinica novedosa y sus derivados.
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
US20210040467A1 (en) 2018-01-30 2021-02-11 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
CN114957482A (zh) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途
KR20230001260A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230001254A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
WO2023068485A1 (ko) * 2021-10-22 2023-04-27 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물
CA3234608A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
KR20240051355A (ko) * 2022-10-12 2024-04-22 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
NZ569541A (en) * 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US8273865B2 (en) * 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
PT2854840T (pt) 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
WO2016149404A1 (en) 2015-03-16 2016-09-22 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
JP7152392B2 (ja) 2022-10-12
IL263058B1 (en) 2023-07-01
AU2017277905A1 (en) 2018-12-20
AU2017277905B2 (en) 2022-04-14
CA3026492A1 (en) 2017-12-14
EA201892784A1 (ru) 2019-05-31
US20190300869A1 (en) 2019-10-03
KR20190025906A (ko) 2019-03-12
JP2022112031A (ja) 2022-08-01
MX2018015254A (es) 2019-08-16
SG11201810210UA (en) 2018-12-28
SG10201912099TA (en) 2020-02-27
IL263058A (en) 2018-12-31
IL263058B2 (en) 2023-11-01
WO2017214447A1 (en) 2017-12-14
US11104891B2 (en) 2021-08-31
JP2019523015A (ja) 2019-08-22
CN109476713A (zh) 2019-03-15
EP3468985A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
BR112018075363A2 (pt) neurotoxinas botulínicas manipuladas
BR112014029585A2 (pt) neurotoxina botulínica engendrada
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2019000151A (es) Una neurotoxina botulinica novedosa y sus derivados.
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
BR112019023071A2 (pt) proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
BR112017014060A2 (pt) composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
BR112016018598A2 (pt) vetor de vírus adeno-associados
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
BR112018003782A2 (pt) composições e métodos para o tratamento da dor
BR112017007202A2 (pt) receptores de célula t
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
BR112018007154A2 (pt) polipeptídeo de ligação a pd-l1, proteína de fusão ou conjugado, complexo, polinucleotídeo, e composição
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112015008844A8 (pt) composições e métodos relacionados a uma toxina de clostridium difficile mutante
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112018003753A2 (pt) bifidobacterium longum
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
BR112016019735A2 (pt) fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica
BR112019023337A2 (pt) Ligase engenheirada, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da ligase engenheirada, um produto de ligação, uma biblioteca de dna e uma pluralidade de fragmentos de dna adequados para sequenciamento, e, composição
BR112017011398A2 (pt) métodos e composições que usam polipeptídeos variantes de klotho

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.